What was the primary endpoint of EMPA-REG OUTCOME?

The primary endpoint was 3-point MACE: a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Empagliflozin reduced this composite by 14% compared to placebo (HR 0.86, p = 0.04).

Did empagliflozin reduce heart attacks in the trial?

No. Nonfatal MI showed a nonsignificant trend toward reduction (HR 0.87, p = 0.22). The primary composite result was driven almost entirely by the 38% reduction in cardiovascular death.

How quickly did the cardiovascular benefit appear?

The Kaplan-Meier curves for cardiovascular death and heart failure hospitalization separated within the first 2 to 3 months. This rapid onset supports a hemodynamic mechanism rather than anti-atherosclerotic plaque stabilization.

Does the trial apply to patients without established heart disease?

EMPA-REG OUTCOME enrolled only patients with established atherosclerotic CVD. Primary prevention patients were excluded. DECLARE-TIMI 58 (dapagliflozin) included a primary prevention subgroup and showed heart failure benefit but not mortality benefit in that population.

Is the benefit specific to empagliflozin or shared across SGLT2 inhibitors?

Subsequent CVOTs for canagliflozin (CANVAS) and dapagliflozin (DECLARE-TIMI 58) showed consistent heart failure benefits, supporting a class effect. The mortality signal was strongest in EMPA-REG OUTCOME, but this may reflect the higher-risk enrolled population.

What are the most common side effects of empagliflozin?

Genital mycotic infections are the most frequent adverse effect (roughly 6% in women, 1 to 2% in men). Urinary tract infections, volume depletion, and rare euglycemic diabetic ketoacidosis are also documented. The Jardiance prescribing information provides the full safety profile.

Did EMPA-REG OUTCOME change the FDA label for Jardiance?

Yes. In 2016, the FDA updated the Jardiance label to include an indication for reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. It was the first diabetes drug to receive this indication.

Can empagliflozin be used in patients with kidney disease?

EMPA-REG OUTCOME excluded patients with eGFR <30. The subsequent EMPA-KIDNEY trial demonstrated renal benefits down to eGFR 20. Current guidelines support use in CKD, though glucose-lowering efficacy diminishes at lower eGFR values while cardiorenal benefits persist.

Why do guidelines now recommend SGLT2 inhibitors regardless of HbA1c?

Because the cardiovascular and heart failure benefits in EMPA-REG OUTCOME and subsequent trials were independent of glycemic control. The 2022 ADA Standards of Care explicitly state that SGLT2 inhibitor initiation should not depend on whether a patient's HbA1c is at target.

Should empagliflozin be stopped before surgery?

Standard guidance is to hold SGLT2 inhibitors 3 to 4 days before elective surgery to reduce the risk of euglycemic diabetic ketoacidosis. Perioperative fasting, stress, and reduced insulin dosing can combine with SGLT2 inhibition to produce ketoacidosis at normal blood glucose levels.

What EMPA-REG OUTCOME Actually Changes in Clinical Practice

Q: Why do guidelines now recommend SGLT2 inhibitors regardless of HbA1c?

Because the cardiovascular and heart failure benefits in EMPA-REG OUTCOME and subsequent trials were independent of glycemic control. The 2022 ADA Standards of Care explicitly state that SGLT2 inhibitor initiation should not depend on whether a patient's HbA1c is at target.

Q: Should empagliflozin be stopped before surgery?

Standard guidance is to hold SGLT2 inhibitors 3 to 4 days before elective surgery to reduce the risk of euglycemic diabetic ketoacidosis. Perioperative fasting, stress, and reduced insulin dosing can combine with SGLT2 inhibition to produce ketoacidosis at normal blood glucose levels.

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

| Detail | Value | |---|---| | N | 7,020 | | Intervention | Empagliflozin 10 mg or 25 mg daily | | Comparator | Placebo (on top of standard care) | | Duration | Median 3.1 years | | Primary endpoint | 3-point MACE (CV death, nonfatal MI, nonfatal stroke) | | Key result | 14% relative risk reduction in MACE (HR 0.86 to 95% CI 0.74, 0.99, p = 0.04) |

Why This Trial Exists

Before 2015, every oral diabetes drug was approved on glycemic endpoints. The FDA's 2008 guidance mandated cardiovascular outcomes trials (CVOTs) for new diabetes medications, but the expectation was safety confirmation, not superiority. DPP-4 inhibitor CVOTs (SAVOR-TIMI 53, EXAMINE, TECOS) had all shown noninferiority without clear benefit. The field assumed SGLT2 inhibitors would follow the same pattern.

EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established atherosclerotic cardiovascular disease across 42 countries. Participants were randomized to empagliflozin 10 mg, empagliflozin 25 mg, or placebo, all layered on existing standard-of-care therapy. The trial was designed to prove noninferiority for its 3-point MACE composite. It did that, and then showed superiority.

What the Numbers Actually Show

The headline 14% MACE reduction matters less than the component breakdown. Nonfatal MI and nonfatal stroke showed no statistically significant separation from placebo. The entire composite result was driven by a 38% reduction in cardiovascular death (HR 0.62 to 95% CI 0.49, 0.77, p <0.001).

That distinction is critical. This was not a trial showing empagliflozin prevents heart attacks. It was a trial showing empagliflozin prevents cardiovascular death, with the benefit appearing within the first three months of treatment. The speed of separation in the Kaplan-Meier curves surprised the cardiology community because atherosclerotic plaque regression takes years, not weeks.

| Outcome | Empagliflozin (%) | Placebo (%) | Hazard Ratio (95% CI) | p-value | |---|---|---|---|---| | 3-point MACE | 10.5 | 12.1 | 0.86 (0.74, 0.99) | 0.04 | | CV death | 3.7 | 5.9 | 0.62 (0.49, 0.77) | <0.001 | | All-cause mortality | 5.7 | 8.3 | 0.68 (0.57, 0.82) | <0.001 | | HF hospitalization | 2.7 | 4.1 | 0.65 (0.50, 0.85) | 0.002 | | Nonfatal MI | 4.8 | 5.4 | 0.87 (0.70, 1.09) | 0.22 | | Nonfatal stroke | 3.5 | 3.0 | 1.18 (0.89, 1.56) | 0.26 |

The 35% reduction in heart failure hospitalization was a prespecified secondary endpoint that became the clinical headline. Combined with the mortality data, it pointed toward a hemodynamic mechanism rather than an anti-atherosclerotic one.

The Mechanism Debate That Followed

Glucose lowering does not explain these results. The HbA1c difference between arms was modest (approximately 0.3, 0.4 percentage points), and no prior glucose-lowering trial had shown this magnitude of mortality reduction at this speed. Several competing hypotheses emerged in the years following publication.

The leading explanation centers on the osmotic diuresis and natriuresis produced by SGLT2 inhibition. By blocking glucose reabsorption in the proximal tubule, empagliflozin reduces plasma volume, lowers preload, and decreases cardiac filling pressures. This would explain the rapid onset of benefit and the heart failure signal. Additional proposed mechanisms include reduced arterial stiffness, improved myocardial energetics through ketone body utilization, and decreased sympathetic nervous system activity.

No single mechanism has been proven definitive. What matters for prescribing is that the benefit appears to be a class-level hemodynamic effect rather than a drug-specific anti-atherosclerotic one. Subsequent SGLT2 inhibitor CVOTs (CANVAS for canagliflozin, DECLARE-TIMI 58 for dapagliflozin) showed consistent heart failure benefits, confirming the class effect hypothesis.

The HealthRX Practice-Change Framework for EMPA-REG OUTCOME

Clinicians reading trial results need a structured way to translate them into prescribing decisions. Here is how we break down the practice implications of EMPA-REG OUTCOME across four domains.

1. Who clearly benefits (high-confidence prescribing)? Patients matching the trial population: type 2 diabetes with established atherosclerotic CVD (prior MI, prior stroke, or peripheral artery disease). This group has the strongest evidence base. Every major guideline now recommends an SGLT2 inhibitor for these patients regardless of baseline HbA1c.

2. Who probably benefits (extrapolation supported by later data)? Patients with type 2 diabetes and heart failure (with or without established ASCVD). The EMPEROR-Reduced and EMPEROR-Preserved trials extended empagliflozin's heart failure evidence to patients with and without diabetes, across the ejection fraction spectrum.

3. Who was excluded and remains uncertain? EMPA-REG OUTCOME excluded patients with eGFR <30 mL/min/1.73m². While the EMPA-KIDNEY trial later showed renal benefit down to eGFR 20, clinicians should recognize that the original cardiovascular mortality data does not directly apply to advanced CKD populations.

4. Where does the trial not help? Primary prevention. Patients with type 2 diabetes and cardiovascular risk factors but no established disease were not enrolled. DECLARE-TIMI 58 included a primary prevention subgroup and showed heart failure benefit but no mortality benefit in that population. Prescribing empagliflozin for CV mortality reduction in primary prevention patients overstates the evidence.

Which Guidelines Actually Changed

The 2018 ADA/EASD consensus report was the first to place SGLT2 inhibitors as preferred second-line therapy after metformin for patients with established ASCVD or heart failure. This was a direct response to EMPA-REG OUTCOME and CANVAS.

By the 2022 ADA Standards of Care, the recommendation was stronger: SGLT2 inhibitors should be considered independent of metformin use and independent of HbA1c. The glycemic hierarchy was officially dismantled for patients with cardiorenal comorbidities.

The 2022 AHA/ACC/HFSA heart failure guidelines went further, recommending SGLT2 inhibitors as foundational therapy for heart failure across the ejection fraction spectrum, regardless of diabetes status. Empagliflozin and dapagliflozin both received Class I recommendations.

The FDA label for Jardiance (empagliflozin) was updated in 2016 to include a cardiovascular death indication, making it the first diabetes medication to carry an FDA-approved CV benefit claim.

Limitations the Authors Acknowledged

The trial population was 72% male, 72% White, and 100% established CVD. Generalizability to women, non-White populations, and primary prevention patients is limited by design, not by data failure.

Both empagliflozin doses (10 mg and 25 mg) were pooled for the primary analysis. While prespecified, this pooling makes it impossible to determine a dose-response relationship from the trial alone. Post hoc analyses suggested similar benefit at both doses, which is consistent with the hemodynamic mechanism hypothesis.

Open-label use of additional glucose-lowering agents was permitted, and more placebo-arm patients added insulin or sulfonylureas during follow-up. This differential co-intervention could theoretically bias results, though it would bias toward the null (making the treatment effect harder to detect, not easier).

The nonfatal stroke signal (HR 1.18, nonsignificant) generated concern. While not statistically significant and potentially a chance finding in the context of multiple endpoints, it has not been replicated in other SGLT2 inhibitor trials and is generally considered a statistical artifact rather than a true safety signal.

What Prescribing Patterns Actually Shifted

Real-world data from the years following EMPA-REG OUTCOME showed a dramatic but uneven uptake. SGLT2 inhibitor prescriptions by cardiologists increased substantially, but endocrinologists remained the primary prescribers through 2020. Primary care adoption lagged further.

The gap between guideline recommendations and prescribing reality persists. A 2023 analysis of US claims data found that fewer than 15% of eligible patients with T2D and established CVD were receiving an SGLT2 inhibitor. Cost, formulary restrictions, and clinical inertia remain barriers. The patent cliff for empagliflozin (expected in the mid-2020s) may accelerate adoption as generic versions become available.

One pattern that did shift immediately: the standard CVOT design. After EMPA-REG OUTCOME, sponsors began powering trials for superiority rather than noninferiority. The GLP-1 receptor agonist CVOTs (LEADER, SUSTAIN-6, REWIND) were analyzed with superiority testing, and the field's expectations for new diabetes drugs permanently changed.

For the Patient Sitting in Front of You

If a patient has type 2 diabetes and has had a heart attack, stroke, or has peripheral artery disease, the evidence from EMPA-REG OUTCOME supports starting empagliflozin regardless of their current HbA1c. The benefit is cardiovascular, not glycemic.

If a patient has heart failure, the EMPEROR trials extend the indication beyond the original EMPA-REG population. If a patient has CKD with albuminuria, EMPA-KIDNEY provides the renal rationale.

The most common reasons patients discontinue SGLT2 inhibitors are genital mycotic infections (occurring in approximately 6% of women and 1 to 2% of men in the trial) and volume depletion symptoms. Neither is dangerous in most cases, but both require proactive counseling at initiation.

Euglycemic diabetic ketoacidosis remains a rare but serious risk. It is most relevant in patients who are insulin-dependent, acutely ill, or perioperative. Standard practice is to hold SGLT2 inhibitors 3 to 4 days before planned surgery.

Frequently asked questions

›

References

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. PubMed
Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. PubMed
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. PubMed
The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-127. PubMed
Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the ADA and EASD. Diabetes Care. 2018;41(12):2669-2701. PubMed
FDA. Jardiance (empagliflozin) prescribing information. accessdata.fda.gov